Ten years ago, when Josh Makower, MD, started an incubator, ExploraMed Inc., it was arguably the device industry's first. Makower proposed a different model for device company creation: to begin without a clear idea of the business, but, backed by some money and a vision of the clinical need, to search for the right technology to address that need. Now, a year after selling one of the incubator's start-ups, TransVascular, to Medtronic, Makower has resurrected ExploraMed, and he's just funded his first company. While the model remains largely the same, subtle differences between ExploraMed I and ExploraMed II highlight how much the medical device start-up world has changed over the past decade.
Ten years ago, Josh Makower, MD, started an incubator,
ExploraMed Inc. , arguably the device
industry's first, at a time when few people in the medical device
industry felt there was any need for incubators. After all, device
company creation was roaring ahead, backed by an eager venture
capital community just discovering medical technology and a public
investor market that was eagerly embracing the promise implicit in
the products that device companies offered.
Over the next several years, however, ExploraMed and the device start-up community went in somewhat separate directions. While the incubator...
Zimmer Biomet is preparing to introduce iodine-coated hip implants to international markets, offering joint replacement patients a new alternative intended to ward off infection. The company intends to broaden the platform’s reach into “knees, shoulders and other categories in due time.”
Ahead of Exact Science’s $21bn dollar acquisition by Abbott, Medtech Insight spoke to the company’s chief medical officer, Tomasz Beer, to learn more about the company’s multi-cancer early detection offering, its wider portfolio of products and to hear more about the direction of the field.
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
With this acquisition, GE HealthCare is trying to accelerate the shift toward integrated solutions including hardware, software, cloud and workflow tools rather than standalone hardware – an area peers will also need to pursue to defend margins. Analysts expect near-term EPS dilution.
A subfield of AI aims to explain why complex models make predictions, which will increase their interpretability and auditing ability, AI researcher Su-In Lee said during a National Academies of Sciences workshop.
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
